Introduction {#s1}
============

Urothelial carcinoma (UC), mainly consisting of upper tract urothelial carcinoma (UTUC) and urothelial carcinoma of the bladder (UCB), is, respectively estimated to have 85,000 new incidences and 18,000 related mortality in the United States in 2018. These made UC become the 4th and 12th most common malignance for males and females ([@B1]). Multiple lesions, high rate of recurrences, and distant metastasis are typical features of UC. Despite advances in surgical techniques and developments of preoperative and postoperative adjuvant therapy, the long-term survival of cases with UC have not significantly changed over these years ([@B2]). Especially, for patients with advanced UC, median overall survival was only 3 to 6 months without therapy, and prolonged to 13--16 months when receiving systematic chemotherapy ([@B3]). Therefore, it is important to determine prognostic factors for timely adjustment of treatment.

Previous literatures have found that cancer cells metabolize differently from normal cells, which means more lactate seems to be needed for cancer cells ([@B4]). Lactate dehydrogenase (LDH), an enzyme that catalyzes lactic acid into pyruvate, may exert a crucial role in the metabolism of tumor cells. High level of serum LDH has been reported to serve as an unfavorable prognostic factor in kinds of malignances, including prostate cancer, renal cell carcinoma, lymphoma, colorectal cancer, and lung cancer ([@B5]). Moreover, many studies have identified the prognostic role of pretreatment serum LDH in cases with UC. Because circulating blood LDH is easy to be measured clinically, it can be used as an indicator of cancer burden and a useful biomarker in clinical management. In the present study, we aimed to systematic review literatures studying the prognostic role of pretreatment LDH in UC and merged the quantitative data.

Methods {#s2}
=======

Study Design
------------

The present study was performed according to the PRISMA statements ([Supplementary Material](#SM1){ref-type="supplementary-material"}) ([@B6]). The protocol has been registered on PROSPERO (No. CRD42019147216).

Literature Searching
--------------------

In order to examine the prognostic significance of serum lactate dehydrogenase in urothelial carcinoma, we searched databases PubMed, Embase, Cochrane Library, and Web of Science up to February 2020 to identify related literatures. The following major terms were used to constitute the search strategy: "lactate dehydrogenase" (e.g., "lactate dehydrogenase," "LDH," "lactic dehydrogenase"), "urothelial carcinoma" (e.g., "urothelial carcinoma," "transitional cell carcinoma," "urothelial tumor," "urothelial cancer"), and "prognosis" (e.g., "prognosis," "survival," "progression," "recurrence," "mortality," "outcome"). Additionally, we manually screened literature references to identify relevant studies. There was no language restriction in the process of literature searching.

Selection Criteria
------------------

In general, the present study included literatures investigating the prognostic role of pretreatment of serum lactate dehydrogenase (LDH) in patients with urothelial carcinoma, and detailed criteria were shown as follows. Inclusion criteria: (1) studies involving patients confirmed diagnosed with urothelial carcinoma; (2) studies that measured serum lactate dehydrogenase of patients before treatment; (3) studies that reported the results of oncological outcomes including overall survival (OS), cancer-specific survival (CSS), and disease-free survival (DFS); (4) studies that directly provided hazard ratios (HRs) and 95% confidence interval (CI) or required data for calculating them. The methods for calculation were reported by Tierney et al. ([@B7]). Exclusion criteria: (1) studies wherein we cannot extract HRs and 95% CI; (2) studies that did not analyze serum lactate dehydrogenase as dichotomous variable or did not clearly report the cut-off value; (3) not original article, such as review, abstract, opinion, letter, and so on; (4) duplicated results from the same cohort. Two researchers independently screened and evaluated the literature; the disputes were resolved by discussion.

Data Extraction and Quality Assessment
--------------------------------------

These two important steps were independently performed by two researchers, and the disputes were resolved by discussion. According to a pre-designed table, items of data extraction included the first author\'s last name, publication year, belonging country, number of subjects included, patient\'s age, cancer type (urothelial carcinoma, upper tract urothelial carcinoma, or urothelial carcinoma of bladder), cancer stage, cut-off value and decision method, therapies that patients underwent, endpoints of oncological outcomes, HRs and 95% CIs (from univariate or multivariate Cox analysis), follow-up durations, and adjusted variables in multivariate Cox analysis.

The quality of each study was evaluated using the Newcastle--Ottawa scale, which embraced three aspects including patient selection, comparability, assessment of outcome, and follow-ups.

Statistical Analysis
--------------------

We extracted all HRs and 95% CIs of related endpoints from included studies. Subgroup analyses of overall survival were also conducted. The grouping variables included publication year, region, site of malignance, number of patients, cancer stage, cut-off value, and NOS score. Meta-regression was also performed to identify the resources of interstudy heterogeneity. Subgroup analyses of upper tract urothelial carcinoma (UTUC) and urothelial carcinoma of the bladder (UCB) were also performed. HRs and the corresponding 95% CI were used to assess the significance of the prognostic value of serum lactate dehydrogenase for urothelial carcinoma. A pooled value \>1 was regarded as indicating an unfavorable outcome for the subjects having a high level of serum lactate dehydrogenase. Cochran\'s Q test and Higgins *I*^2^ statistic were both conducted to examine inter-study heterogeneity. A random effects model was applied for all analyses. Publication bias was assessed by funnel plots, Egger\'s, and Begg\'s tests. Sensitivity analysis was performed to check the stability of the results. All statistical analyses were performed with Stata 12.0 (STATA Corporation, College Station, TX, USA).

Results {#s3}
=======

Study Searching and Screening
-----------------------------

The flowchart of this process is presented in ([Figure 1](#F1){ref-type="fig"}). Database searching identified 143 articles, and no additional study was found by checking the references. Eighty-five studies were remained after excluding duplicated records. Title and abstract screening, respectively, excluded 40 and 25 literatures, then 20 studies were assessed with full text. Since there were four studies wherein hazard ratio data cannot be obtained ([@B8]--[@B11]), and two studies had no peripheral blood date ([@B12], [@B13]), 14 literatures were included last for data extraction ([@B2], [@B14]--[@B25]).

![Flowchart of study searching and screening.](fonc-10-00677-g0001){#F1}

Baseline features of the included studies are shown in ([Table 1](#T1){ref-type="table"}). Nine studies were published recently (2013--2020) by Chinese and Japanese researchers ([@B2], [@B14]--[@B20], [@B26]). Five studies were published 16 years (1993--2002) ago by Chinese and European researchers ([@B21]--[@B25]). The median or mean age of patients ranged from 60.3 to 73 years, and the sample size ranged from 56 to 1,087. Seven studies focused on urothelial carcinoma ([@B14], [@B16], [@B19], [@B22]--[@B24], [@B26]), three focused on UTUC ([@B2], [@B17], [@B18]), and four focused on UCB ([@B15], [@B20], [@B21], [@B25]). Of all 40 studies, 10 provided results of multivariable Cox analysis ([@B2], [@B14], [@B15], [@B17]--[@B20], [@B22], [@B25], [@B26]). The adjusted factors embraced clinical, pathological, and laboratorial variables, which are detailed in ([Table 2](#T2){ref-type="table"}). All studies were of low-to-moderate risk of bias, the NOS score ranged from 6 to 8, which are presented in ([Table 3](#T3){ref-type="table"}).

###### 

Baseline features of included studies.

  **References**              **Country**   **Sample size**   **Age (years)**   **Cancer type**   **Cancer stage**          **Cut-off value (U/l)**   **Decision method**   **Therapy**                **Survival analysis**
  --------------------------- ------------- ----------------- ----------------- ----------------- ------------------------- ------------------------- --------------------- -------------------------- -----------------------
  Suzuki et al. ([@B26])      Japan         185               70 (64--76)       UC                Advanced                  360                       LRM                   All                        Multivariate
  Takemura et al. ([@B19])    Japan         125               70 (64--74)       UC                Advanced                  246                       Reported              All                        Multivariate
  Tan et al. ([@B2])          China         668               65.8 ± 11.4       UTUC              All                       220                       Normal                All                        Multivariate
  Nakagawa et al. ([@B15])    Japan         1087              69 (63--75)       UCB               Recurrent                 ULN                       Normal                All                        Multivariate
  Abe et al. ([@B16])         Japan         228               67 (30--83) R     UC                Metastatic                200                       \-                    Chemotherapy               Univariate
  Zhang et al. ([@B17])       China         100               60.3 mean         UTUC              Localized                 245                       Normal                Surgery                    Multivariate
  Ito et al. ([@B18])         Japan         71                \-                UTUC              Localized                 210                       Normal                Surgery                    Multivariate
  Fukushima et al. ([@B19])   Japan         88                68 (39--91)R      UC                Advanced                  ULN                       Normal                All                        Multivariate
  Nakagawa et al. ([@B20])    Japan         114               67(32--84)R       UCB               Recurrent                 ULN                       Normal                All                        Multivariate
  Yang et al. ([@B21])        China         310               \-                UCB               Advanced                  200                       Reported              Surgery and chemotherapy   Univariate
  Yang et al. ([@B22])        China         535               71 (31--88) R     UC                All                       200                       Reported              All                        Multivariate
  Bellmunt et al. ([@B23])    Spain         56                \-                UC                Advanced                  ULN                       Normal                Chemotherapy               Univariate
  Sengelov et al. ([@B24])    Denmark       240               67 (37--86)R      UC                Recurrent or metastatic   ULN                       Normal                Surgery and chemotherapy   Univariate
  Hannisdal et al. ([@B25])   Norway        202               73 (32--85)R      UCB               Localized                 400                       \-                    Radiotherapy               Multivariate

*UC, urothelial carcinoma; UTUC, upper tract urothelial carcinoma; UCB, urothelial carcinoma of the bladder; ULN, upper limit of normal; LRM, linear regression model; R, range*.

###### 

Follow-up and oncological outcomes.

  **References**              **Follow-up duration, month**   **Outcomes**   **Adjusted factors**
  --------------------------- ------------------------------- -------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Suzuki et al. ([@B26])      12.3                            OS             Age, performance status, BMI, primary tumor site, alkaline phosphatase, C-reactive protein, albumin, lymphocyte count, Pembrolizumab after chemotherapy failure
  Takemura et al. ([@B19])    12.1                            OS             Age, Karnofsky performance status, primary site, neutrophil-to-lymphocyte ratio, γ-glutamyltransferase, C-reactive protein, systemic chemotherapy
  Tan et al. ([@B2])          45 (21--74)                     OS, CSS, DFS   Tumor grade, concomitant variant histology, lymphovascular invasion, tumor size, tumor architecture, surgical margin status, perioperative blood transfusion, anemia, pT stage, lymph node status, alpha-hydroxybutyrate dehydrogenase, alkaline phosphatase, albumin, globulin, white blood cells, adjuvant therapy
  Nakagawa et al. ([@B15])    6.8 (3.0--15.8)                 OS             Age, pT stage, lymph node density, time-to-recurrence, symptom, number of involved organs/sites, local recurrence, bone metastasis, liver metastasis, lung metastasis, hemoglobin level, leukocyte count, platelet count, total protein, albumin, alkaline phosphatase, C-reactive protein, estimated glomerular filtration rate, treatments after recurrence, era of recurrence
  Abe et al. ([@B16])         17 (14--19)                     OS             \-
  Zhang et al. ([@B17])       45.8 (1--151)R                  OS, DFS        Pathological stage, lymph node status, subsequent bladder tumor, tumor grade, multifocality, vascular invasion, tumor necrosis, architecture
  Ito et al. ([@B18])         50.3 (1--160)R                  DFS            Clinical T stage
  Fukushima et al. ([@B19])   13 (1--99)R                     OS             Primary site, alkaline phosphatase, C-reactive protein, sarcopenia
  Nakagawa et al. ([@B20])    11.0 (0.2--206.7)R              OS             Time-to-recurrence, symptoms at recurrence, no metastatic organs, C-reactive protein, post-recurrent chemotherapy with platinum agent, metastasectomy
  Yang et al. ([@B21])        71 (1--132)R                    CSS            \-
  Yang et al. ([@B22])        81 (1--144)R                    OS             Urbanization, from endemic "blackfoot disease" area, age, sex, histologic grade, T stage, lymph node metastases, distant metastases, serum creatinine level
  Bellmunt et al. ([@B23])    15.8 (11.9--19.5)               OS             \-
  Sengelov et al. ([@B24])    3.6 (0.1--62.4)R                OS             \-
  Hannisdal et al. ([@B25])   18                              OS             T stage, ESR, age, albumin

*OS, overall survival; CSS, cancer-specific survival; DFS, disease-free survival; BMI, body mass index; ESR, erythrocyte sedimentation rate; R, range*.

###### 

Newcastle--Ottawa scale for risk of bias assessment.

  **References**              **Selection**   **Comparability**   **Outcome**   **Overall**                   
  --------------------------- --------------- ------------------- ------------- ------------- --- --- --- --- -------
  Suzuki et al. ([@B26])      1               1                   1             1             1   1   1   1   **8**
  Takemura et al. ([@B19])    0               1                   1             1             1   1   1   1   **7**
  Tan et al. ([@B2])          1               1                   1             1             1   1   0   1   **7**
  Nakagawa et al. ([@B15])    1               1                   1             1             1   1   1   1   **8**
  Abe et al. ([@B16])         1               1                   1             1             0   1   1   1   **7**
  Zhang et al. ([@B17])       0               1                   1             1             1   1   0   1   **6**
  Ito et al. ([@B18])         0               1                   1             1             1   1   0   1   **6**
  Fukushima et al. ([@B19])   0               1                   1             1             1   1   1   1   **7**
  Nakagawa et al. ([@B20])    0               1                   1             1             1   1   1   1   **7**
  Yang et al. ([@B21])        1               1                   1             1             0   1   1   0   **6**
  Yang et al. ([@B22])        1               1                   1             1             1   1   1   1   **8**
  Bellmunt et al. ([@B23])    0               1                   1             1             0   1   1   1   **6**
  Sengelov et al. ([@B24])    1               1                   1             1             0   1   1   1   **7**
  Hannisdal et al. ([@B25])   1               1                   1             1             1   1   0   1   **7**

Urothelial Carcinoma
--------------------

First, all included studies were analyzed together. For the three endpoints (overall survival, cancer-specific survival, disease-free survival), there were 12 ([@B2], [@B14]--[@B17], [@B19], [@B20], [@B22]--[@B26]), 2 ([@B2], [@B21]), and 3 ([@B2], [@B17], [@B18]) studies, respectively, that reported related results. After merging HRs and 95% CIs, we identified that a high pretreatment serum LDH was associated with an inferior overall survival (HR 1.61, 95% CI 1.39--1.87, *p* \< 0.001), cancer-specific survival (HR 1.41, 95% CI 1.05--1.90, *p* = 0.022), and disease-free survival (HR 1.64, 95% CI 1.04--2.59, *p* = 0.034) in patients with urothelial carcinoma ([Figure 2](#F2){ref-type="fig"}). Subgroup analyses of overall survival were also conducted, and the results are presented in ([Table 4](#T4){ref-type="table"}). The subgroup variables included year of publication, region, site of carcinoma, sample size, survival analysis, and NOS score, which did not obviously change the results. Moreover, except for survival analysis (*p* = 0.033), other subgroup variables were not the resources of inter-study heterogeneity (*P* \> 0.05 for all).

![Forest plots of studies about urothelial carcinoma.](fonc-10-00677-g0002){#F2}

###### 

Subgroup analyses for overall survival in urothelial carcinoma.

  **Subgroup**          **Studies**   **HR (95% CI)**     ***P* value**   **Meta-regression *P* value**   **Heterogeneity**   
  --------------------- ------------- ------------------- --------------- ------------------------------- ------------------- -------
  Year of publication                                                     0.845                                               
  2016--2020            6             1.78 (1.31--2.43)   \<0.001                                         54.0                0.054
  1993--2015            6             1.59 (1.33--1.90)   \<0.001                                         0.0                 0.846
  Region                                                                  0.350                                               
  Asia                  9             1.64 (1.40--1.93)   \<0.001                                         33.7                0.148
  Non-Asia              3             1.47 (1.18--1.83)   \<0.001                                         0.0                 0.911
  Site of carcinoma                                                       0.355                                               
  Upper urinary tract   2             1.82 (1.16--2.84)   0.009                                           41.3                0.192
  Bladder               3             1.71 (1.37--2.15)   \<0.001                                         0.0                 0.548
  All                   7             1.48 (1.25--1.75)   \<0.001                                         29.8                0.201
  Sample size                                                             0.084                                               
  \> 200                6             1.48 (1.28--1.71)   \<0.001                                         0.0                 0.425
  \<200                 6             2.04 (1.53--2.71)   \<0.001                                         0.0                 0.537
  Survival analysis                                                       0.033                                               
  Multivariable         9             1.82 (1.53--2.15)   \<0.001                                         0.0                 0.695
  Univariate            3             1.30 (1.06--1.59)   0.010                                           0.0                 0.586
  NOS score                                                               0.106                                               
  \>7                   3             2.00 (1.50--2.66)   \<0.001                                         0.0                 0.386
  \< =7                 9             1.49 (1.29--1.72)   \<0.001                                         0.0                 0.457

*HR, hazard ratio; CI, confidence interval; NOS, Newcastle--Ottawa Scale*.

UTUC and UCB
------------

Subgroup analyses of UTUC and UCB were also performed. There were three and three studies, respectively, that were included in the subgroup analyses of UTUC ([@B2], [@B17], [@B18]) and UCB ([@B15], [@B20], [@B25]). After merging HRs and 95% CIs, we identified that a high pretreatment serum LDH was associated with a poor overall survival (HR 1.97, 95% CI 1.02--3.81, *p* = 0.042) and disease-free survival (HR 1.64, 95% CI 1.04--2.59, *p* = 0.034) in patients with UTUC ([Figure 3A](#F3){ref-type="fig"}). A high pretreatment serum LDH was associated with a short overall survival (HR 1.71, 95% CI 1.37--2.15, *p* \< 0.001) in patients with UCB ([Figure 3B](#F3){ref-type="fig"}).

![Forest plots of studies about upper tract urothelial carcinoma and urothelial carcinoma of the bladder. **(A)** Upper tract urothelial carcinoma; **(B)** urothelial carcinoma of the bladder.](fonc-10-00677-g0003){#F3}

Publication Bias and Sensitivity Analysis
-----------------------------------------

Since most analyses embraced insufficient literatures, we only checked publication bias and performed sensitivity analysis for overall survival of patients with urothelial carcinoma. The funnel plot showed an approximately asymmetric result, and quantitative tests identified significant differences (Begg\'s test: *p* = 0.024; Egger\'s test: *p* = 0.005) ([Figure 4A](#F4){ref-type="fig"}). The result of sensitivity analysis showed that excluding any study did not significantly change the merged data ([Figure 4B](#F4){ref-type="fig"}).

![Funnel plot and sensitivity analysis for overall survival of urothelial carcinoma. **(A)** Funnel plot; **(B)** sensitivity analysis.](fonc-10-00677-g0004){#F4}

Discussion {#s4}
==========

Previous literatures have found that cancer cells metabolize differently from normal cells. Even with sufficient oxygen, malignant cells will preferentially metabolize glucose through glycolysis to produce adequate energy for growth, which is known as the Warburg effect and is one of the major metabolic changes in the process of malignant transformation ([@B4]). The serum level of LDH, the enzyme involved in the glycolytic pathway, can reflect the metabolic alterations ([@B27]). A high level of serum LDH has been reported to serve as an unfavorable prognostic factor in several types of malignances. Several studies have examined the prognostic role of LDH in subjects with UC and have reported inconsistent results. Hence, the present systematic review and meta-analysis about this issue was performed.

After systematic literature searching and screening, 14 studies embracing 4,009 patients were included. All studies were of low-to-moderate risk of bias, and the NOS score ranged from 6 to 8. The HRs and 95% CIs extracted from these studies were merged. The results showed that a high pretreatment serum LDH was associated with an inferior overall survival, cancer-specific survival, and disease-free survival in UC. Subgroup analyses of OS showed that grouping variable did not obviously change the results. Moreover, sensitivity analysis further confirmed the stability and reliability of the results. Subgroup analyses of UTUC and UCB were also performed. We identified that a high pretreatment serum LDH was associated with a poor overall survival and disease-free survival in UTUC, a short overall survival in UCB. Since circulating blood LDH is easy to be measured clinically, it can be used as an indicator of cancer burden and a useful biomarker in management of UC.

For the prognostic significance of pretreatment LDH in cases with UC, only one meta-analysis previously was reported. In 2016, Zhang et al. ([@B28]) performed a meta-analysis to evaluate the prognostic role of LDH for cases with urological cancer. They included two studies about bladder cancer and one study about UTUC. A high level of serum LDH has been reported to serve as an unfavorable prognostic factor. With more and later studies being included, the present study may provide more comprehensive and reliable results for this issue.

Metabolically, the most prominent feature of cancer cells is an increase in lactic acid production due to their increased glucose uptake rate and reduced oxidative phosphorylation rate, regardless of the availability of oxygen. The phenomenon, called aerobic glycolysis, was first discovered 70 years ago by Otto Warburg ([@B4]). As an important substance of the Warburg effect, LDH exists in nearly all kinds of tissues, which has six different isoenzymes. These isoenzymes are assembled from two protein subunits, LDHA and LDHB, into a homo- or hetero-tetramer structure ([@B29]). The third protein subunit, called LDHC, forms the testicular specific subtype LDH-6 ([@B30]). The main function of lactate dehydrogenase is to catalyze the reversible reaction between pyruvate and lactic acid. NAD^+^ is produced along with this process and is necessary for the continuous production of ATP to maintain glycolysis. Among the LDH isoforms, LDH-5 has the highest catalytic efficiency ([@B31]). When cancer tissue is necrotic, high intracellular LDH levels are released into the blood, increasing serum LDH concentrations ([@B32]). In addition, when distant metastases occur, tumor cells can damage adjacent organs, such as the lung, liver, and bone. Damage to these organs can also increase serum LDH levels ([@B31], [@B33]--[@B35]). In conclusion, serum LDH seems to be a significant factor in the development of malignance. Its level can reflect tumor burden and serve as cancer biomarker.

There were several limitations for the present study. First, due to limited literatures, we studied all types and stages of UC together. The differences in type, stage, and treatment for UC may be the sources of inter-study heterogeneity. Despite both belonging to UC, UTUC, and UCB may have different biological behaviors and disease characteristics. Hence, subgroup analyses of UTUC and UCB were also performed. Second, serum LDH may be affected by other non-tumor diseases, such as anemia, hepatic disease, muscular dystrophy, and heart failure, which have not been examined in these studies. Moreover, the present study also included results from univariable analysis. These uncontrolled factors may affect the results, and the methods of survival analysis have been found to be the source of inter-study heterogeneity. Third, taken that different cut-off values were used in the included literatures, it is a problem to choose the best one, which may affect the application of this biomarker in clinical practice. Fourth, a significant publication bias was found in the meta-analysis of overall survival, which cannot be overcome by statistical methods. Regardless, the present study represents the most comprehensive and latest systematic review and meta-analysis about the prognostic role of LDH in patients with UC.

In general, the present study proved that a high level of pretreatment serum LDH was associated with inferior OS, CSS, and DFS in patients with UC. Moreover, an elevated level of serum LDH was associated with poor OS and DFS in patients with UTUC, a short OS in patients with UCB. Despite more high-level studies were needed to verify our results, the level of serum LDH can be an important factor incorporated into the prognostic models for UC.
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